Genetic variants and family history predict prostate cancer similar to prostate-specific antigen

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 1105-1111

  Zheng, S Lilly ^a   Sun, Jielin ^a   Wiklund, Fredrik ^b   Gao, Zhengrong ^a   Stattin, Pär ^c   Purcell, Lina D ^a   Adami, Hans Olov ^b,d   Hsu, Fang Chi ^a   Zhu, Yi ^a   Adolfsson, Jan ^b   Johansson, Jan Erik ^e   Turner, Aubrey R ^a   Adams, Tamara S ^a   Liu, Wennuan ^a   Duggan, David ^f   Carpten, John D ^f   Chang, Bao Li ^a   Isaacs, William B ^g,i   Xu, Jianfeng ^a,h   Grönberg, Henrik ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^g DEPARTMENT OF PATHOLOGY   (United States)

^h Center for Human Genomics   (United States)

ⁱ JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RISK; FAMILY HISTORY; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AREA UNDER CURVE; CASE-CONTROL STUDIES; FAMILY HEALTH; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 61549109900     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1743     Document Type: Article

References (29)

1. Weir HK,Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-99.
2. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70.
3. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
4. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA1998;279:1542-7.
5. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62: 2695-8.
6. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64:311-5.
7. Leman ES, Cannon GW,Trock BJ, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007;69:714-20.
8. Diamandis EP. POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma? Clin Biochem 2007;40:1437-9.
9. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38:652-8.
10. Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006;103:14068-73.
11. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39:631-7.
12. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-9.
13. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39:977-83.
14. Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007;99:1836-44.
15. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genom e-wide association study of prostate cancer. Nat Genet 2008;40:310-5.
16. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008;40:281-3.
17. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-21.
18. HaimanCA,PattersonN,FreedmanML,etal. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007;39:638-44.
19. Zheng SL, Sun J, Cheng Y, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst. 2007;99:1525-33.
20. Severi G, Hayes VM, Padilla EJ, et al. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16:610-2.
21. Wang L, McDonnell SK, Slusser JP, et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007;67:2944-50.
22. Schumacher FR, Feigelson HS, Cox DG, et al. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 2007;67:2951-6.
23. Suuriniemi M, Agalliu I, Schaid DJ, et al. Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 2007;16:809-14.
24. Robbins C,Torres JB, Hooker S, et al. Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res 2007;17:1717-22.
25. Cheng I, Plummer SJ, Jorgenson E, et al. 8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet 2008;16:496 -505.
26. Sun J, Purcell L, Gao Z, et al. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate 2008;68:691-7.
27. Zheng SL, Sun J,Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358:910-9.
28. Adolfsson J, Garmo H, Varenhorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007;12:1-22.
29. De Long ER, De Long DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics1988;44:837-45.